Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Digital tools are becoming increasingly important across veterinary medicine, from clinical workflows to client communication and practice operations.

According to the announcement, Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment. The development is relevant because it reflects how animal health companies, service providers, and technology platforms are responding to changing expectations in veterinary care.

What Was Announced

Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections in dogs and is administered by a veterinary health professional, supporting complete dose compliance. “Anyone who has tried to give a dog pills for a week or two knows how challenging it can be to stay on schedule.

Convenia® (cefovecin sodium) has been a veterinarian-trusted treatment for susceptible bacterial skin infections for over a decade and has helped remove the burden of continued and accurate dosing that is typically required with oral antibiotics,” said Abhay Nayak, Executive Vice President and President, U.S. Commercial Operations at Zoetis. “With Convenia RTU for Dogs, we are building on the established Convenia portfolio with a formulation designed for use in dogs of all sizes.” Convenia RTU for Dogs joins Convenia, an injectable medication approved by the FDA in 2008 to treat susceptible bacterial skin infections in cats and dogs.

Why This Matters for Veterinary Professionals

For veterinary professionals, technology announcements matter when they affect efficiency, access to care, diagnostics, reimbursement, or the daily workflow of the clinic.

At the practice level, the most relevant question is whether the development can reduce administrative friction, improve access to information, or support more consistent communication between veterinary teams and clients.

Industry Perspective

The animal health industry continues to move toward more connected, data-driven services for veterinary practices and pet owners.

While individual announcements should be interpreted in the context of their source, they can help veterinary professionals monitor where investment, innovation, and market attention are moving across the animal health sector.

Original announcement: Zoetis — https://www.businesswire.com/news/home/20261020644906/en/Zoetis-Receives-FDA-Approval-for-Convenia-RTU-for-Dogs-cefovecin-injectable-suspension-Helping-More-Medium-and-Large-Dogs-Access-Single-Injection-Treatment